HHHouyuan Hu

Houyuan Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Houyuan Hu has a total of 113 co-authors. Here are the top co-authors by number of shared publications:

  • Jianxiang Zhang

    Department of Pharmaceutics College of Pharmacy Third Military Medical University (Army Medical University) Chongqing China

    7 shared publications
  • Wei-Bo Zhao

    Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing 400038, P.R. China

    5 shared publications
  • Juan Cheng

    Department of Obstetrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400042, China

    4 shared publications
  • Lina Pan

    Department of Cardiology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China

    4 shared publications
  • Qiang Chen

    Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing 400038, P.R. China

    4 shared publications
  • Cheng Sun

    Department of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing 400038, P.R. China

    3 shared publications

Latest Publications

  • Open Access

    Association Between Inflammation Indices Derived From Complete Blood Count and Coronary Artery Calcification

    by Yi He, Lian Li, Ting Zhou, Hao Yang, Tao Liu, Houyuan Hu

    Background: Inflammation plays an important role in the pathogenesis of coronary artery calcification (CAC). This study aims to explore the potential association between inflammation indices derived from complete blood count (CBC) and CAC, including the neutrophil to lymphocyte ratio (NLR), derived neutrophil to lymphocyte ratio (dNLR), neutrophil-monocyte to lymphocyte ratio (NMLR), systemic inflammation response index (SIRI), systemic immune-inflammation index (SII), aggregate index of systemic inflammation (AISI), platelet to lymphocyte ratio (PLR), and monocyte to lymphocyte ratio (MLR). Methods: We systematically collected data from patients who underwent CAC scoring via cardiac CT at our hospital between July 2018 and June 2023. Patients were divided into two groups based on the presence or absence of CAC. Multivariate logistic regression analysis, smooth curve fitting, and threshold effect analysis were subsequently used to explore the potential linear or nonlinear relationships between CBC-derived inflammation indices and CAC. Subgroup analyses were conducted to examine the consistency of these findings across different subgroups. Results: A total of 2143 participants were included in this study: the CAC group (1286 participants) and the non-CAC group (857 participants). In the four subgroups of CAC, within-group comparisons revealed that alkaline phosphatase (ALP), smoking status, and peripheral artery plaques were more prevalent in the group with CAC scores > 400. After adjusting for confounding variables, we found that the total NLR, NMLR, SIRI, and AISI were positively associated with CAC. Subsequently, we identified a nonlinear relationship between MLR and CAC, with a threshold value of 0.236. Additionally, subgroup analysis indicated that these associations remained stable across various subgroups. Conclusion: This study indicates that the total NLR, NMLR, SIRI, and AISI are significantly positively correlated with CAC in a linear association, while MLR exhibits a nonlinear relationship with CAC. In contrast, SII, PLR, and dNLR show no significant association with CAC.


  • Platelets in Vascular Calcification: A Comprehensive Review of Platelet-Derived Extracellular Vesicles, Protein Interactions, Platelet Function Indices, and their Impact on Cellular Crosstalk

    by Yi He, Qiongyue Zhang, Lina Pan, Hao Yang, Tao Liu, Junjie Bei, Karlheinz Peter, Houyuan Hu

    Vascular calcification (VC) commonly accompanies the development of atherosclerosis, defined by the accumulation of calcium in the arterial wall, potentially leading to stroke and myocardial infarction. Severe and unevenly distributed calcification poses challenges for interventional procedures, elevating the risks of vascular dissection, acute vascular occlusion, restenosis, and other major adverse cardiovascular events. Platelets promote the development of atherosclerosis by secreting various inflammatory mediators, regulating cell migration, aggregation, adhesion, and initiating and expanding inflammatory responses. There is emerging evidence that platelets play a direct role in VC; however, this novel concept has not yet been critically assessed. This review describes the intricate mechanisms by which platelets promote VC, focusing on three key aspects and the potential opportunities for their therapeutic targeting: extracellular vesicles, platelet-regulatory proteins, and indices related to platelet function. * These authors contributed equally. Article published online: 27 August 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA


  • Melatonin ameliorates atherosclerosis by suppressing S100a9-mediated vascular inflammation

    by Liyuan Chen, Xue Wang, Chang Liu, Ping Deng, Lina Pan, Lingling Yang, Juan Cheng, Xutao Zhang, Russel J. Reiter, Zhengping Yu, et al.


  • Efficacy and Safety of Aspirin Combined with Low-Dose P2Y12 Receptor Antagonists in East Asian Patients Undergoing PCI

    by Xiankang Hu, Weibo Zhao, Qiongyue Zhang, Houyuan Hu, Suxin Luo

    Previous studies have indicated that low-dose new generation of P2Y12 receptor antagonists may be more suitable compared with clopidogrel at a standard dose for the dual antiplatelet therapy (DAPT) for East Asian patients receiving percutaneous coronary intervention (PCI). However, there remains no consensus in clinical practice. Thus, in this study, we aimed to determine the efficacy and safety of low-dose P2Y12 receptor antagonists, compared to clopidogrel at a standard dose, in DAPT in East Asian patients after PCI. We systematically searched literatures for randomized controlled trials (RCT) comparing low-dose P2Y12 receptor antagonists with standard-dose clopidogrel for the treatment of East Asian patients undergoing PCI. The endpoints of efficacy include major adverse cardiac events (MACEs), all-cause mortality, and the number of target vessel revascularization. The indicators of safety include major and minor bleeding events. Heterogeneity was evaluated by I2 statistic test. Begg's and Egger's tests were used to evaluate publication bias. In total, 2,747 subjects from 8 RCT studies were included. Low-dose new P2Y12 receptor antagonists, that is, ticagrelor or prasugrel, showed significantly lower incidence of MACEs, as compared with standard-dose clopidogrel, in the East Asian patients who are in DAPT after undergoing PCI. Further, no difference was noted for the risk of major and minor bleeding events. In East Asian patients undergoing PCI and receiving DAPT, the use of low-dose P2Y12 receptor antagonists, ticagrelor or prasugrel, has been determined to be superior than clopidogrel at standard dose; this has been evidenced by a lower incidence of MACEs without increasing the risk of bleeding.


  • Open Access

    Pulmonary circulation-mediated heart targeting for the prevention of heart failure by inhalation of intrinsically bioactive nanoparticles

    by Chao Liu, Liyuan Chen, Yongchang Ma, Kaiyao Hu, Peng Wu, Lina Pan, Haiyan Chen, Lanlan Li, Houyuan Hu, Jianxiang Zhang

    Heart failure is a serious clinical and public health problem. Currently there is an unmet demand for effective therapies for heart failure. Herein we reported noninvasive inhalation delivery of nanotherapies to prevent heart failure.


  • Association between heart rate variability indices and features of spontaneous ventricular tachyarrhythmias in mice

    by Mi He, Wei‐Bo Zhao, My‐Nhan Nguyen, Helen Kiriazis, Yong‐Qin Li, Houyuan Hu, Xiao‐Jun Du

    Direct evidence is limited for the association between heart rate variability (HRV) indices and ventricular tachyarrhythmias (VTAs). Whilst galectin‐3 (Gal‐3) is regarded as a causal factor for cardiac remodeling and a biomarker for arrhythmias, its regulation on VTAs and HVR is unknown. Using aged transgenic (TG) mice with cardiac overexpression of β2‐adrenoceptors and spontaneous VTAs, we studied whether changes in HRV indices correlated with the severity of VTAs, and whether Gal‐3 gene knockout (KO) in TG mice might limit VTA. Body‐surface ECG was recorded (10‐min period) in 9‐10 month‐old mice of non‐transgenic (nTG), TG and TG×Gal‐3 knockout (TG/KO). Time‐domain, frequency‐domain and nonlinear‐domain HRV indices were calculated using the R‐R intervals extracted from ECG signals and compared with frequency of VTAs. TG and TG/KO mice developed frequent VTAs and showed significant changes in certain time‐domain and non‐linear domain HRV indices relative to nTG mice. The severity of VTAs in TG and TG/KO mice in combination, estimated by VTA counts and arrhythmia score, was significantly correlated with certain time‐domain and nonlinear‐domain HRV indices. In conclusion, significant changes in HRV indices were evident and correlated with the severity of spontaneous VTAs in TG mice. The frequency of VTA and HRV indices were largely comparable between TG and TG/KO mice. Deletion of Gal‐3 in TG mice altered certain HRV indices implying influence by neuronally localized Gal‐3 on autonomic nervous activity.


  • Open Access

    A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases

    by Runjun Zhang, Renfeng Liu, Chao Liu, Lina Pan, Yuantong Qi, Juan Cheng, Jiawei Guo, Yi Jia, Jun Ding, Jianxiang Zhang, et al.


  • Cyclodextrin‐Derived Intrinsically Bioactive Nanoparticles for Treatment of Acute and Chronic Inflammatory Diseases

    by Jiawei Guo, Dandan Li, Hui Tao, Gang Li, Renfeng Liu, Yin Dou, Taotao Jin, Lanlan Li, Jun Huang, Houyuan Hu, et al.

    Inflammation is a common cause of many acute and chronic inflammatory diseases. A major limitation of existing anti‐inflammatory therapeutics is that they cannot simultaneously regulate pro‐inflammatory cytokine production, oxidative stress, and recruitment of neutrophils and macrophages. To overcome this limitation, nanoparticles (NPs) with multiple pharmacological activities are synthesized, using a chemically modified cyclic oligosaccharide. The manufacture of this type of bioactive, saccharide material‐based NPs (defined as LCD NP) is straightforward, cost‐effective, and scalable. Functionally, LCD NP effectively inhibits inflammatory response, oxidative stress, and cell migration for both neutrophils and macrophages, two major players of inflammation. Therapeutically, LCD NP shows desirable efficacies for the treatment of acute and chronic inflammatory diseases in mouse models of peritonitis, acute lung injury, and atherosclerosis. Mechanistically, the therapeutic benefits of LCD NP are achieved by inhibiting neutrophil‐mediated inflammatory macrophage recruitment and by preventing subsequent pro‐inflammatory events. In addition, LCD NP shows good safety profile in a mouse model. Thus, LCD NP can serve as an effective anti‐inflammatory nanotherapy for the treatment of inflammatory diseases mainly associated with neutrophil and macrophage infiltration.


  • Open Access

    Activation of the STAT3/microRNA‐21 pathway participates in angiotensin II‐induced angiogenesis

    by Li‐Yuan Chen, Xue Wang, Xiao‐Long Qu, Li‐Na Pan, Ze‐Yang Wang, Yong‐Hui Lu, Hou‐Yuan Hu

    Angiotensin II (AngII) facilitates angiogenesis that is associated with the continuous progression of atherosclerotic plaques, but the underlying mechanisms are still not fully understood. Several microRNAs (miRNAs) have been shown to promote angiogenesis; however, whether miRNAs play a crucial role in AngII‐induced angiogenesis remains unclear. This study evaluated the functional involvement of miRNA‐21 (miR‐21) in the AngII‐mediated proangiogenic response in human microvascular endothelial cells (HMECs). We found that AngII exerted a proangiogenic role, indicated by the promotion of proliferation, migration, and tube formation in HMECs. Next, miR‐21 was found to be upregulated in AngII‐treated HMECs, and its specific inhibitor potently blocked the proangiogenic effects of AngII. Subsequently, we focused on the constitutive activation of STAT3 in the AngII‐mediated proangiogenic process. Bioinformatic analysis indicated that STAT3 acted as a transcription factor initiating miR‐21 expression, which was verified by ChIP‐PCR. A reporter assay further identified three functional binding sites of STAT3 in the miR‐21 promoter region. Moreover, phosphatase and tensin homolog (PTEN) was recognized as a target of miR‐21, and STAT3 inhibition restored AngII‐induced reduction in PTEN. Similarly, the STAT3/miR‐21 axis was shown to mediate AngII‐provoked angiogenesis in vivo, which was demonstrated by using the appropriate inhibitors. Our data suggest that AngII was involved in proangiogenic responses through miR‐21 upregulation and reduced PTEN expression, which was, at least in part, linked to STAT3 signaling. The present study provides novel insights into AngII‐induced angiogenesis and suggests potential treatment strategies for attenuating the progression of atherosclerotic lesions and preventing atherosclerosis complications.